Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 10/20 | 0.65 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.63 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.63 |
| ▸ | GPR34 | Q9UPC5 | 4/20 | 0.57 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.56 |
| ▸ | GPR174 | Q9BXC1 | 3/20 | 0.54 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29238665 | 1.00 | P2RY10 (0.65) | P2RY10LPAR1LPAR3GPR34LPAR2 | |
| SCHEMBL30763305 | 0.99 | P2RY10 (0.67) | P2RY10LPAR1LPAR3GPR34LPAR2 | |
| SCHEMBL4291753 | 0.99 | P2RY10 (0.67) | P2RY10LPAR1LPAR3GPR34LPAR2 | |
| SCHEMBL31358896 | 0.99 | P2RY10 (0.67) | P2RY10LPAR1LPAR3GPR34LPAR2 | |
| SCHEMBL28614391 | 0.99 | P2RY10 (0.67) | P2RY10LPAR1LPAR3GPR34LPAR2 | |
| SCHEMBL2235432 | 0.93 | P2RY10 (0.61) | P2RY10LPAR1LPAR3GPR34GPR174 | |
| SCHEMBL29059592 | 0.92 | P2RY10 (0.78) | P2RY10GPR34GPR174 | |
| SCHEMBL4165745 | 0.92 | P2RY10 (0.78) | P2RY10GPR34GPR174 | |
| SCHEMBL30989240 | 0.90 | P2RY10 (0.72) | P2RY10GPR34GPR174 | |
| SCHEMBL29285069 | 0.90 | P2RY10 (0.72) | P2RY10GPR34GPR174 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023190176-A1 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | 日油株式会社 | 2023-10-05 | — | — | WO | claimed |
| US-11116818-B2 | Compositions and methods for inhibiting viral entry | Children's Medical Center Corporation Dana-Farber Cancer Institute (US) | 2021-09-14 | — | — | US | claimed |
| US-9889183-B2 | PKC activators and anticoagulant in regimen for treating stroke | WEST VIRGINIA UNIVERSITY (US) | 2018-02-13 | — | — | US | claimed |
| US-20160184414-A1 | PKC ACTIVATORS AND ANTICOAGULANT IN REGIMEN FOR TREATING STROKE | WEST VIRGINIA UNIVERSITY | 2016-06-30 | — | — | US | claimed |
| US-20150297677-A1 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ENTRY | CHILDREN MEDICAL CENTER CORPORATION (US) | 2015-10-22 | — | — | US | claimed |
| EP-2931317-A2 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ENTRY | Children's Medical Center Corporation (US) | 2015-10-21 | — | — | EP | claimed |
| US-9107890-B2 | PKC activators and anticoagulant in regimen for treating stroke | BLANCHETTE ROCKEFELLER NEUROSCIENCES INSTITUTE (US) | 2015-08-18 | — | — | US | claimed |
| WO-2014093627-A2 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ENTRY | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-06-19 | — | — | WO | claimed |
| US-20240148918-A1 | Loading of Alginate Microspheres | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-05-09 | — | — | US | disclosed |
| US-20240082197-A1 | DELIVERY METHODS FOR OMEGA-3'S AND COMPOSITIONS FOR VITAMINS AND MINERALS USED TO ENHANCE VISUAL ACUITY AND MENTAL DEVELOPMENT IN THE HUMAN BODY | VIVA LIFE SCIENCE INC (US) | 2024-03-14 | — | — | US | disclosed |
| US-20240058454-A1 | BIOLOGICAL DELIVERY SYSTEMS | PARTICELLA INC (US) | 2024-02-22 | — | — | US | disclosed |
| US-11878057-B2 | Immunomodulatory lipopolysaccharide compositions | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-01-23 | — | — | US | disclosed |
| WO-2024014512-A1 | LYOPHILIZED COMPOSITION OF NUCLEIC-ACID-LOADED LIPID NANOPARTICLES | 日油株式会社 | 2024-01-18 | — | — | WO | disclosed |
| WO-2024011118-A2 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER BY TARGETING ONCOGENIC TRANSFER RNAS | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-01-11 | — | — | WO | disclosed |
| WO-2002088318-A2 | LIPID-COMPRISING DRUG DELIVERY COMPLEXES AND METHODS FOR THEIR PRODUCTION | TARGETED GENETICS CORPORATION (US) | 2002-11-07 | — | — | WO | disclosed |
| WO-2002036161-A2 | NOVEL TARGETED COMPOSITIONS FOR DIAGNOSTIC AND THERAPEUTIC USE | IMARX THERAPEUTICS, INC. (US) | 2002-05-10 | — | — | WO | disclosed |
| EP-1146911-A2 | NOVEL METHODS OF IMAGING AND TREATMENT WITH TARGETED COMPOSITIONS | IMARX PHARMACEUTICAL CORP. (US) | 2001-10-24 | — | — | EP | disclosed |
| WO-2001068081-A1 | AGENT FOR TREATING ILLNESSES OF THE TRACHEOBRONCHIAL TRACT, ESPECIALLY CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH (DE) | 2001-09-20 | — | — | WO | disclosed |
| WO-2000045856-A2 | NOVEL METHODS OF IMAGING AND TREATMENT WITH TARGETED COMPOSITIONS | IMARX PHARMACEUTICAL CORP. (US) | 2000-08-10 | — | — | WO | disclosed |
| US-5329029-A | Phosphatidylalkanolamine derivatives and their use in generating phospholipid conjugates | GENZYME CORPORATION | 1994-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184414-A1 | PKC ACTIVATORS AND ANTICOAGULANT IN REGIMEN FOR TREATING STROKE | PRKCZ, PRKCA, PRKCB | P2RY10 1827/4885LPAR1 1737/4885LPAR3 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.